Fulcrum Therapeutics, Inc.
Companies
1993-2019
Filing Dates

23 filings

Newest first
10-Q
2019 Q3
FULC Fulcrum Therapeutics, Inc.
14 Nov 19
Quarterly report
8-K
FULC Fulcrum Therapeutics, Inc.
14 Nov 19
Fulcrum Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
8-K
FULC Fulcrum Therapeutics, Inc.
4 Oct 19
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
10-Q
2019 Q2
FULC Fulcrum Therapeutics, Inc.
26 Aug 19
Quarterly report
S-8
FULC Fulcrum Therapeutics, Inc.
26 Aug 19
Registration of securities for employees
8-K
FULC Fulcrum Therapeutics, Inc.
26 Aug 19
Results of Operations and Financial Condition
SC 13G
FULC Fulcrum Therapeutics, Inc.
29 Jul 19
Fulcrum Therapeutics, Inc.
SC 13G
Foresite Capital Fund IV, L.P.
27 Jul 19
Fulcrum Therapeutics, Inc.
8-K
FULC Fulcrum Therapeutics, Inc.
22 Jul 19
Amendments to Articles of Incorporation or Bylaws
424B4
FULC Fulcrum Therapeutics, Inc.
18 Jul 19
Prospectus supplement with pricing info
EFFECT
FULC Fulcrum Therapeutics, Inc.
18 Jul 19
Notice of effectiveness
CORRESP
FULC Fulcrum Therapeutics, Inc.
15 Jul 19
Correspondence with SEC
CORRESP
FULC Fulcrum Therapeutics, Inc.
15 Jul 19
Correspondence with SEC
8-A12B
FULC Fulcrum Therapeutics, Inc.
12 Jul 19
Registration of securities on exchange
S-1/A
FULC Fulcrum Therapeutics, Inc.
12 Jul 19
IPO registration (amended)
S-1/A
FULC Fulcrum Therapeutics, Inc.
8 Jul 19
IPO registration (amended)
S-1
FULC Fulcrum Therapeutics, Inc.
21 Jun 19
IPO registration
DRS/A
FULC Fulcrum Therapeutics, Inc.
6 Jun 19
Draft registration statement (amended)
DRS
FULC Fulcrum Therapeutics, Inc.
1 May 19
Draft registration statement
D
FULC Fulcrum Therapeutics, Inc.
5 Sep 18
$80M in equity, sold $80M, 20 investors